SCHEMBL6668503

SCHEMBL6668503

Cc1ccc(-c2ccccc2C(=O)Nc2ccc3c(c2)CCN3C(=O)Cc2ccccn2)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EIF2AK3 Q9NZJ5 1/20 0.51
SMO Q99835 2/20 0.50
MAPT P10636 3/20 0.48
NPC1 O15118 1/20 0.48
TP53 P04637 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CREBBP Q92793 1/20 0.44
AVPR2 P30518 5/20 0.43
NAMPT P43490 2/20 0.42
SYK P43405 1/20 0.42
HTR2C P28335 2/20 0.42
HTR2B P41595 2/20 0.42
HTR2A P28223 1/20 0.42
AVPR1A P37288 2/20 0.42
POLB P06746 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6664580 0.99 EIF2AK3 (0.50) EIF2AK3SMOMAPTNPC1TP53
SCHEMBL6802672 0.94 EIF2AK3 (0.50) EIF2AK3SMOMAPTNPC1TP53
SCHEMBL6667964 0.94 EIF2AK3 (0.50) EIF2AK3SMOMAPTNPC1TP53
SCHEMBL6809248 0.93 SMO (0.56) EIF2AK3SMOTP53CREBBPAVPR2
SCHEMBL6804490 0.92 EIF2AK3 (0.50) EIF2AK3SMOMAPTNPC1TP53
SCHEMBL6798695 0.92 HTR2C (0.49) EIF2AK3SMOMAPTNPC1TP53
SCHEMBL6803254 0.92 EIF2AK3 (0.48) EIF2AK3SMOMAPTNPC1TP53
SCHEMBL6670489 0.92 EIF2AK3 (0.49) EIF2AK3SMOMAPTNPC1TP53
SCHEMBL6799240 0.92 EIF2AK3 (0.49) EIF2AK3SMOMAPTNPC1TP53
SCHEMBL6672281 0.92 EIF2AK3 (0.49) EIF2AK3SMONPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157866-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-12 US disclosed
EP-1383760-A1 BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-28 EP disclosed
WO-2002090347-A1 AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157866-A1 Amide compounds APOB, NR1H2, NR1H3 EIF2AK3 2638/4885SMO 4390/4885MAPT 4047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.